Friday, April 03, 2026 | 03:27 PM ISTहिंदी में पढें
Concord Biotech Ltd News
Antique maintains 'Buy' on Concord Biotech; sees strong API, CDMO growth
Antique expects the Concord to report revenue, Ebitda and PAT CAGR of 18 per cent, 17 per cent and 19 per cent, respectively, with margins remaining stable at around 42 per cent over FY25-28E
 "Antique maintains 'Buy' on Concord Biotech; sees strong API, CDMO growth")
Updated On : 06 Jan 2026 | 10:10 AM IST
Antique prefers domestic-focused pharma firms; resumes coverage on 4 stocks
Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating
 "Antique prefers domestic-focused pharma firms; resumes coverage on 4 stocks")
Updated On : 29 Dec 2025 | 11:24 AM IST